Are risk factors associated with invasive pneumococcal disease according to different serotypes?

অনুরূপ উপাদানগুলি

• Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study
  অনুযায়ী: Domínguez, Ángela, অন্যান্য
  প্রকাশিত: (2017)
• Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era
  অনুযায়ী: Izquierdo, C., অন্যান্য
  প্রকাশিত: (2020)
• Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Pandemic and Nonpandemic Influenza Periods
  অনুযায়ী: Hernández, Sergi, অন্যান্য
  প্রকাশিত: (2019)
• Erratum for Hernández et al., “Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Epidemic and Nonepidemic Influenza Periods”
  অনুযায়ী: Hernández, Sergi, অন্যান্য
  প্রকাশিত: (2020)
• Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study
  অনুযায়ী: Hernández, Sergi, অন্যান্য
  প্রকাশিত: (2020)